Subscribe to Entrepreneur for $5
Subscribe

The Zacks Analyst Blog Highlights: Salesforce, Intuit, Bristol-Myers Squibb, QUALCOMM and Lockheed Martin

The Zacks Analyst Blog Highlights: Salesforce, Intuit, Bristol-Myers Squibb, QUALCOMM and Lockheed Martin

By
This story originally appeared on Zacks

For Immediate Release

Chicago, IL – December 29, 2021 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: salesforce.com, inc. CRM, Intuit Inc. INTU, Bristol-Myers Squibb Company BMY, QUALCOMM Incorporated QCOM and Lockheed Martin Corporation LMT.

- Zacks

Here are highlights from Tuesday’s Analyst Blog:

Top Research Reports for salesforce, Intuit and Bristol-Myers Squibb

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Salesforce, Intuit, and Bristol-Myers Squibb. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.

You can see all of today’s research reports here >>>

Shares of salesforce have underperformed the Zacks Computer Software industry over the past year (+16.1% vs. +41.9%), however, things seem to be improving for it. The Zacks analyst believes that salesforce has been benefiting from a robust demand environment on the back of the ongoing digital transformation.

The rapid adoption of its cloud-based solutions has also been driving demand for its products. CRM’s sustained focus on introducing more products aligned with customer needs is another positive. The recent acquisition of Slack is likely to position CRM as a leader in enterprise team collaboration solution space. Stiff competition and unfavorable currency fluctuations, however, remain as major concerns for salesforce.

(You can read the full research report on salesforce here >>>)

Intuit shares have gained +72.7% in the year to date period against the Zacks Computer Software industry’s gain of +42.3%. The Zacks analyst believes that Intuit has been benefiting from strong momentum in online ecosystem revenues as well as professional tax revenues.

The TurboTax Live offering is also driving growth in the Consumer tax business. INTU’s strategy of shifting its business to cloud-based subscription model is likely to generate stable revenues in the long run. Pandemic related global lockdowns, higher expenses due to increased investments in marketing and engineering teams are some of the major concerns though.

(You can read the full research report on Intuit here >>>)

Shares of Bristol-Myers have gained +3.6% in the last three months against the Zacks Biomedical and Genetics industry’s loss of -14.4%. The Zacks analyst believes that strong sales of drugs like Opdivo, Revlimid and Eliquis are likely to continue driving BMY’s top line. Bristol-Myers’ efforts to develop its pipeline are also encouraging.

The label expansion of Opdivo into indications of lung cancer, renal cancer and gastric cancer has been boosting sales. The approval of new drugs like Reblozyl will add a new stream of revenues, which should also boost growth. Generic competition as well as pipeline setbacks, however, remain as major threats.

(You can read the full research report on Bristol-Myers here >>>)

Other noteworthy reports we are featuring today include Qualcomm and Lockheed Martin.

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339

support@zacks.com                                      

https://www.zacks.com                                          

 

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.



More Stock News: This Is Bigger than the iPhone!

It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 77 billion devices by 2025, creating a $1.3 trillion market.

Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 4 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2022.

Click here for the 4 trades >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

 

Lockheed Martin Corporation (LMT): Free Stock Analysis Report

 

QUALCOMM Incorporated (QCOM): Free Stock Analysis Report

 

salesforce.com, inc. (CRM): Free Stock Analysis Report

 

Bristol Myers Squibb Company (BMY): Free Stock Analysis Report

 

Intuit Inc. (INTU): Free Stock Analysis Report

 

To read this article on Zacks.com click here.